The WACC of Inogen Inc (INGN) is 6.8%.
Range | Selected | |
Cost of equity | 6.5% - 10.9% | 8.7% |
Tax rate | 1.2% - 4.7% | 2.95% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 5.7% - 7.8% | 6.8% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 0.57 | 1.07 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 6.5% | 10.9% |
Tax rate | 1.2% | 4.7% |
Debt/Equity ratio | 1 | 1 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 5.7% | 7.8% |
Selected WACC | 6.8% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
INGN | Inogen Inc | 0.83 | 1.21 | 0.67 |
ARAY | Accuray Inc | 1.03 | 2.05 | 1.02 |
AWH | Aspira Women's Health Inc | 1.01 | -0.53 | -0.26 |
BDX | Becton Dickinson and Co | 0.4 | 0.16 | 0.11 |
CRY | CryoLife Inc | 0.42 | 1.54 | 1.09 |
CSII | Cardiovascular Systems Inc | 0.02 | 0.74 | 0.72 |
CUTR | Cutera Inc | 955.87 | 0.4 | 0 |
NTUS | Natus Medical Inc | 0 | 0.23 | 0.23 |
OFIX | Orthofix Medical Inc | 0.37 | 1.05 | 0.77 |
TCMD | Tactile Systems Technology Inc | 0.11 | 0.5 | 0.45 |
VAPO | Vapotherm Inc | 7.9 | -0.47 | -0.05 |
Low | High | |
Unlevered beta | 0.23 | 0.67 |
Relevered beta | 0.36 | 1.1 |
Adjusted relevered beta | 0.57 | 1.07 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for INGN:
cost_of_equity (8.70%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.57) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.